<div id="readability-page-1"><p>Sight Sciences, Inc. (NASDAQ:SGHT - Get Free Report) insider Jeremy Hayden sold 1,785 shares of the business's stock in a transaction that occurred on Tuesday, January 6th. The stock was sold at an average price of $7.48, for a total value of $13,351.80. Following the sale, the insider owned 245,420 shares of the company's stock, valued at approximately $1,835,741.60. This trade represents a 0.72% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link.</p><div><p><span></span><span>Get <strong>Sight Sciences</strong> alerts:</span></p></div><h2>Sight Sciences Price Performance</h2><p>Shares of NASDAQ SGHT traded down $0.24 during midday trading on Tuesday, hitting $7.47. The stock had a trading volume of 197,717 shares, compared to its average volume of 290,394. The company has a quick ratio of 8.93, a current ratio of 9.60 and a debt-to-equity ratio of 0.62. The stock has a 50 day simple moving average of $7.52 and a 200-day simple moving average of $5.13. The company has a market capitalization of $394.94 million, a PE ratio of -8.30 and a beta of 2.42. Sight Sciences, Inc. has a 1 year low of $2.03 and a 1 year high of $9.24. </p><p>Sight Sciences (NASDAQ:SGHT - Get Free Report) last issued its quarterly earnings results on Wednesday, September 8th. The company reported ($0.81) EPS for the quarter. The firm had revenue of $12.54 million for the quarter. Sight Sciences had a negative return on equity of 61.59% and a negative net margin of 60.63%. On average, sell-side analysts expect that  Sight Sciences, Inc. will post -0.99 EPS for the current fiscal year. </p><h2>Key Sight Sciences News</h2><p>Here are the key news stories impacting Sight Sciences this week:</p><ul>   <li><span>Positive Sentiment: </span>Piper Sandler upgraded Sight Sciences to Overweight (from Neutral), a buy-side analyst upgrade that can attract investor interest and buying momentum. <i></i><span>Piper Sandler upgrade</span></li>    <li><span>Neutral Sentiment: </span>Despite recent sales, insiders still hold large positions — CEO Paul Badawi (~5.9M shares) and CTO David Badawi (~1.9M shares) retain substantial ownership, which can indicate alignment with long-term value even as they trim stakes. <i></i><span>Insider ownership filing</span></li>    <li><span>Negative Sentiment: </span>Clustered insider selling by executives — CEO Paul Badawi, CTO David Badawi, CFO James Rodberg, EVP Brenton Taylor and insider Jeremy Hayden — over Jan. 2–6. Combined disclosed sales total roughly $0.48M across these transactions; each sale was a small percentage (&lt;1%) of the seller’s holdings but the concentrated timing can create downward pressure on the stock. See CEO / executive filings. <i></i><span>CEO sale filing</span> <i></i><span>CTO sale filing</span> <i></i><span>Other insider filings</span></li> </ul><h2>Analyst Upgrades and Downgrades</h2><p>Several brokerages recently issued reports on SGHT. Weiss Ratings  reaffirmed a &#34;sell (e+)&#34; rating on shares of Sight Sciences in a research note on Monday, December 29th. Lake Street Capital boosted their target price on Sight Sciences from $5.00 to $7.00 and gave the stock a &#34;buy&#34; rating in a report on Tuesday, October 21st. Morgan Stanley upped their price target on Sight Sciences from $6.00 to $8.00 and gave the company an &#34;equal weight&#34; rating in a research report on Tuesday, December 2nd. Citigroup lifted their price objective on Sight Sciences from $5.50 to $9.10 and gave the stock a &#34;neutral&#34; rating in a research report on Thursday, December 11th. Finally, Raymond James Financial  set a $9.00 price objective on Sight Sciences in a research note on Monday. Four investment analysts have rated the stock with a Buy rating, three have assigned  a Hold rating and one  has assigned  a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of &#34;Hold&#34; and an average target price of $8.30.</p><p><b>Get Our Latest Stock Analysis on Sight Sciences</b></p><h2>Institutional Investors Weigh In On Sight Sciences</h2><p>A number of institutional investors have recently made changes to their positions in the stock. BNP Paribas Financial Markets lifted its holdings in shares of  Sight Sciences by 99.8% in the 3rd quarter. BNP Paribas Financial Markets now owns 7,579 shares of the company's stock worth $26,000 after acquiring an additional 3,785 shares during the last quarter.  CWM LLC increased its stake in  Sight Sciences by 70.2% during the second quarter. CWM LLC now owns 7,607 shares of the company's stock worth $31,000 after purchasing an additional 3,137 shares during the period.  Tower Research Capital LLC TRC lifted its position in shares of  Sight Sciences by 32.7% during the second quarter. Tower Research Capital LLC TRC now owns 11,665 shares of the company's stock worth $48,000 after purchasing an additional 2,875 shares in the last quarter.  Bank of Montreal Can acquired a new stake in shares of  Sight Sciences during the second quarter worth about $49,000.  Finally, R Squared Ltd purchased a new position in shares of  Sight Sciences in the third quarter valued at approximately $64,000. 55.51% of the stock is currently owned by institutional investors and hedge funds. </p><h2>Sight Sciences Company Profile</h2> (Get Free Report)<p>Sight Sciences, Inc is a medical device company focused on developing and commercializing minimally invasive treatments for chronic eye diseases. The company's flagship products include the OMNI® Surgical System, designed to address multiple points of resistance in the eye's natural drainage pathways to lower intraocular pressure in glaucoma patients, and the TearCare® System, a wearable device for treating meibomian gland dysfunction and dry eye disease through targeted thermal pulsation therapy.  </p><p>Since its founding in 2012 and subsequent listing on the NASDAQ under the ticker SGHT, Sight Sciences has pursued a strategy of combining research-driven product development with a direct sales force model.</p><h2>See Also</h2><ul><li>Five stocks we like better than Sight Sciences</li><li>You Still Think Silver’s a Joke? Watch What Happens Next.</li><li>A month before the crash</li><li>BNZI: BNZI Surges Ahead as AI Marketing Fuels Record Revenue</li><li>“Fed Proof” Your Bank Account with THESE 4 Simple Steps</li><li>S&amp;P 8000</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U0dIVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U0dIVA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Sight Sciences Right Now?</h2><p>Before you consider Sight Sciences, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sight Sciences wasn't on the list.</p><p>While Sight Sciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

SGHT

<p>Jeremy Hayden, an insider at Sight Sciences, Inc. (NASDAQ:SGHT), sold 1,785 shares at an average price of $7.48, totaling $13,351.80. Post-sale, he retains 245,420 shares valued at approximately $1.84 million, marking a 0.72% decrease in ownership. The transaction was disclosed to the SEC. Sight Sciences' stock traded down to $7.47, with a market cap of $394.94 million. Analysts have mixed sentiments, with Piper Sandler upgrading the stock to Overweight, while Weiss Ratings maintains a 'sell' rating. The average target price is $8.30, with four analysts rating it as a Buy.</p>

Jeremy Hayden Sells 1,785 Shares of Sight Sciences (NASDAQ:SGHT) Stock